The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus

Antiviral Research

Volumn 112, Issue , 2014, Pages 1-7

  Garrison, Aura R ^a   Giomarelli, Barbara G ^b   Lear Rooney, Calli M ^a   Saucedo, Carrie J ^b,c   Yellayi, Srikanth ^d   Krumpe, Lauren R H ^b,c   Rose, Maura ^b   Paragas, Jason ^a,e   Bray, Mike ^a,d   Olinger, Gene G ^a   McMahon, James B ^b   Huggins, John ^a   O'Keefe, Barry R ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Cyanobacteria; Ebola; Lectin; Natural product; Scytovirin

Indexed keywords

ANTIVIRUS AGENT; LECTIN; NATURAL PRODUCT; SCYTOVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; BACTERIAL PROTEIN; CARRIER PROTEIN; GLYCOPROTEIN; SCYTOVIRIN PROTEIN, S VARIUM; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; IN VITRO STUDY; IN VIVO STUDY; LIVER; MARBURG VIRUS; NONHUMAN; PROTECTION; PROTEIN DOMAIN; SPLEEN; SURVIVAL; TISSUE INJURY; TREATMENT OUTCOME; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IC50; MARBURGVIRUS; METABOLISM; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; SERUM; SUBCUTANEOUS DRUG ADMINISTRATION; VIROLOGY; VIRUS LOAD;

CYANOBACTERIA; ZAIRE EBOLAVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; INHIBITORY CONCENTRATION 50; INJECTIONS, SUBCUTANEOUS; LECTINS; LIVER; MARBURGVIRUS; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SERUM; SPLEEN; SURVIVAL ANALYSIS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84908404590     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.09.012     Document Type: Article

References (24)

1. Barrientos, L.G., O'Keefe, B.R., et al., 2003. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 58 (1), 47-56.
2. Barton, C., Kouokam, J.C., et al., 2014. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob. Agents Chemother. 58 (1), 120-127.
3. Bokesch, H.R., O'Keefe, B.R., et al., 2003. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42 (9), 2578-2584.
4. Boyd, M.R., Gustafson, K.R., et al., 1997. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41 (7), 1521-1530.
5. Bray, M., Davis, K., et al., 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178 (3), 651-661.
6. Bringans, S.D., O'Keefe, B.R., et al., 2004. Development of a fluorescent microplate assay for determining cyanovirin-N levels in plasma. Anal. Bioanal. Chem. 380 (2), 269-274.
7. Geisbert, T.W., Hensley, L.E., et al., 2003. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362 (9400), 1953-1958.
8. Lee, J.E., Fusco, M.L., et al., 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 10 (454(7201)), 177-182.
9. Lee, J.E., Saphire, E.O., 2009. Ebola virus glycoprotein structure and mechanism of entry. Future Virol. 4 (6), 621-635.
10. McFeeters, R.L., Xiong, C., et al., 2007. The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors. J. Mol. Biol. 369 (2), 451-461.
11. Moe, J.B., Lambert, R.D., et al., 1981. Plaque assay for Ebola virus. J. Clin. Microbiol. 13 (4), 791-793.
12. Mori, T., O'Keefe, B.R., et al., 2005. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.. J. Biol. Chem. 280 (10), 9345-9353.
13. O'Keefe, B.R., Vojdani, F., et al., 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U.S.A. 106 (15), 6099-6104.
14. Pettitt, J., Zeitlin, L., et al., 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5 (199), 199ra113.
15. Radoshitzky, S.R., Warfield, K.L., et al., 2011. Ebola virus delta-peptide immunoadhesins inhibit Marburg virus and Ebola virus cell entry. J. Virol. 85 (17), 8502-8513.
16. Raymond, J., Bradfute, S., et al., 2011. Filovirus infection of STAT-1 knockout mice. J. Infect. Dis. 204 (Suppl. 3), S986-S990.
17. Ritchie, G., Harvey, D.J., et al., 2010. Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 24 (5), 571-585.
18. Takada, A., Robison, C., et al., 1997. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94 (26), 14764-14769.
19. Takebe, Y., Saucedo, C.J., et al., 2013. Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS ONE 8 (5), e64449.
20. Towner, J.S., Paragas, J., et al., 2005. Generation of eGFP expressing recombinant Zaire Ebola virus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332 (1), 20-27.
21. Warren, T.K., Warfield, K.L., et al., 2010. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents Chemother. 54 (5), 2152-2159.
22. Weidmann, M., Muhlberger, E., et al., 2004. Rapid detection protocol for filoviruses. J. Clin. Virol. 30 (1), 94-99.
23. Wong, G., Qiu, W., et al., 2014. Post-exposure therapy of filovirus infections. Trends Microbiol. 22 (8), 456-463.
24. Xiong, C., O'Keefe, B.R., et al., 2006. Overexpression and purification of scytovirin, a potent, novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Protein Expr. Purif. 46 (2), 233-239.